Glemanserin
| Glemanserin | |
|---|---|
| Glemanserin_structure.png | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Glemanserin is a chemical compound that acts as a selective antagonist of the 5-HT2A receptor, a subtype of the serotonin receptor. It has been studied for its potential therapeutic effects in various psychiatric disorders, including schizophrenia and anxiety disorders.
Pharmacology[edit]
Glemanserin is known for its high affinity and selectivity for the 5-HT2A receptor, which is a G protein-coupled receptor (GPCR) involved in the modulation of neurotransmission in the central nervous system. By blocking the action of serotonin at this receptor, glemanserin can alter the activity of neural circuits implicated in mood and perception.
Mechanism of Action[edit]
The primary mechanism of action of glemanserin is the antagonism of the 5-HT2A receptor. This receptor is widely distributed in the brain, particularly in areas such as the prefrontal cortex, hippocampus, and thalamus. By inhibiting the receptor, glemanserin can reduce the excitatory effects of serotonin, potentially leading to anxiolytic and antipsychotic effects.
Clinical Research[edit]
Research into glemanserin has focused on its potential use in treating psychiatric conditions. Studies have explored its efficacy in reducing symptoms of schizophrenia, particularly those related to hallucinations and delusions. Additionally, its role in managing anxiety disorders has been investigated, with some studies suggesting it may help alleviate symptoms of generalized anxiety disorder and panic disorder.
Chemical Structure[edit]
Glemanserin is a small molecule with a specific chemical structure that allows it to bind selectively to the 5-HT2A receptor. The structure of glemanserin includes a core aromatic ring system, which is crucial for its receptor binding properties.
Potential Side Effects[edit]
As with many pharmacological agents, glemanserin may have side effects. Commonly reported side effects include drowsiness, dry mouth, and dizziness. More serious side effects are rare but can include cardiovascular effects such as changes in blood pressure and heart rate.
Related Compounds[edit]
Glemanserin is part of a class of compounds known as 5-HT2A receptor antagonists. Other compounds in this class include ketanserin and ritanserin, which have been studied for similar therapeutic applications.
Related pages[edit]
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
